Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.74 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.71 |
| ▸ | PYGM | P11217 | 1/20 | 0.67 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9796913 | 1.00 | DNPH1 (0.74) | DNPH1P2RY6P2RY2P2RY4PYGM | |
| SCHEMBL28372181 | 1.00 | DNPH1 (0.74) | DNPH1P2RY6P2RY2P2RY4PYGM | |
| SCHEMBL3026247 | 0.91 | P2RY6 (0.78) | DNPH1P2RY6P2RY2P2RY4PYGM | |
| SCHEMBL3026250 | 0.91 | P2RY6 (0.78) | DNPH1P2RY6P2RY2P2RY4PYGM | |
| SCHEMBL17211062 | 0.90 | P2RY6 (0.75) | DNPH1P2RY6P2RY2P2RY4 | |
| SCHEMBL21277458 | 0.90 | P2RY6 (0.75) | DNPH1P2RY6P2RY2P2RY4 | |
| SCHEMBL29515219 | 0.90 | P2RY6 (0.75) | DNPH1P2RY6P2RY2P2RY4 | |
| SCHEMBL2133591 | 0.90 | P2RY6 (0.75) | DNPH1P2RY6P2RY2P2RY4 | |
| SCHEMBL12714923 | 0.90 | P2RY6 (0.75) | DNPH1P2RY6P2RY2P2RY4 | |
| SCHEMBL625390 | 0.90 | P2RY6 (0.75) | DNPH1P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175760-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE WITH mRNA ENCODING GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT (G6PC) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175759-A1 | METHODS OF TREATING A SUBJECT HAVING PROPIONIC ACIDEMIA WITH mRNA ENCODING PROPIONYL-COA CARBOXYLASE, SUBUNIT ALPHA AND/OR BETA (PCCA AND/OR PCCB) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175758-A1 | METHODS OF TREATING A SUBJECT HAVING CITRULLINEMIA WITH mRNA ENCODING ARGININOSUCCINATE SYNTHASE (ASS) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175756-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE II WITH mRNA ENCODING ACID GLUCOSIDASE ALPHA (GAA) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175757-A1 | METHODS OF TREATING A SUBJECT HAVING FRIEDREICH'S ATAXIA WITH mRNA ENCODING FRATAXIN | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190167808-A1 | METHODS OF TREATING PHENYLKETONURIA WITH MRNA ENCODING PHENYLALANINE HYDROXYLASE (PAH) | CUREVAC AG (DE) | 2019-06-06 | — | — | US | claimed |
| US-20190167809-A1 | METHODS OF TREATING A SUBJECT WITH mRNA ENCODING COAGULATION FACTOR VIII (F8) | CUREVAC AG (DE) | 2019-06-06 | — | — | US | claimed |
| US-20180311379-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-11-01 | — | — | US | claimed |
| US-20180236102-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-08-23 | — | — | US | claimed |
| US-20180169266-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-21 | — | — | US | claimed |
| US-20180117179-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-05-03 | — | — | US | claimed |
| US-20170128549-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-05-11 | — | — | US | claimed |
| US-20170065727-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-03-09 | — | — | US | claimed |
| US-20170000858-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-01-05 | — | — | US | claimed |
| US-20160367704-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-12-22 | — | — | US | claimed |
| US-9487825-B2 | Pooled adapter strategy for reducing bias in small RNA characterization | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2016-11-08 | — | — | US | claimed |
| US-20160184406-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-06-30 | — | — | US | claimed |
| US-20120322691-A1 | POOLED ADAPTER STRATEGY FOR REDUCING BIAS IN SMALL RNA CHARACTERIZATION | MOUNT SINAI SCHOOL OF MEDICINE | 2012-12-20 | — | — | US | claimed |
| WO-2012158603-A2 | POOLED ADAPTER STRATEGY FOR REDUCING BIAS IN SMALL RNA CHARACTERIZATION | BIOO SCIENTIFIC CORPORATION (US) | 2012-11-22 | — | — | WO | claimed |
| WO-2009127230-A1 | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION | CUREVAC GMBH (DE) | 2009-10-22 | — | — | WO | claimed |